How Ebola and Marburg virus proteins VP30 and VP24 help the virus copy and exit cells
Contributions of Ebola and Marburg virus VP30 and VP24 proteins to viral RNA synthesis, assembly and egress
This project looks at how two viral proteins, VP30 and VP24, help Ebola and Marburg viruses copy their genetic material and leave infected cells to better understand how these infections cause disease.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11090530 on NIH RePORTER |
What this research studies
Researchers use safe laboratory models that mimic Ebola and Marburg virus replication at lower biosafety levels so they can study the viruses without live BSL‑4 work. They focus on two viral proteins, VP30 and VP24, and use genetic changes, CRISPR tools, and biochemical tests to see how these proteins support RNA synthesis, particle assembly, and virus egress. The team compares the Marburg and Ebola versions of these proteins to identify differences and host factors that interact with them. Results are intended to reveal viral weaknesses that could be targeted by future treatments or prevention strategies.
Who could benefit from this research
Good fit: People who have had Ebola or Marburg, those at risk, or individuals willing to donate clinical samples to research at Washington University or partner sites would be most connected to this project.
Not a fit: Patients needing immediate treatment for an active infection or people without exposure to these viruses are unlikely to get direct short-term benefit from this laboratory-focused project.
Why it matters
Potential benefit: If successful, this work could reveal targets for new antiviral drugs or vaccine strategies that block viral replication or spread in Ebola and Marburg infections.
How similar studies have performed: Related work using virus-like particle systems has helped map viral replication steps and find host interactions, though translating those findings into therapies remains early.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Basler, Christopher F — Washington University
- Study coordinator: Basler, Christopher F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.